Several matter pinch shares of Northstar Asset Management Group Inc. (NYSE:NSAM) [Trend Analysis], as shares plunging -3.41% to $11.89 with a share volume of 5.99 Million. NorthStar Asset Management Group Inc. (NSAM), Colony Capital, Inc. (CLNY) and NorthStar Realty Finance Corp. (NRF) reported that a merger accord under which the companies will combine in an all-stock merger of equals transaction.
The combined company will be named, Colony NorthStar, Inc. NSAM shareholders will own approximately 32.85%, Colony shareholders will own approximately 33.25% and NRF shareholders will own approximately 33.90% of the combined company. NSAM shareholders will also receive, in addition to its regular quarterly dividend, a special cash dividend equal to $128 million, which represents a one-time distribution of excess NSAM taxable earnings and profits. The stock is going forward its 52-week low with 31.93% and moving down from its 52-week high price with -43.21%. To have technical analysis views, debt to equity ratio of 2.58. The float short ratio was 2.47%, as compared to sentiment indicator; Short Ratio was 2.71.
Lion Biotechnologies, Inc. (NASDAQ:LBIO) [Trend Analysis] luring active investment momentum, shares a gain 43.45% to $8.65. Lion Biotech enters private placement w/ institutional investors of ~9.7 million shares of common stock and ~11.4 million shares of Series B Preferred Stock; purchase price will be $4.75/share of common stock (LBIO).
The firm has entered into a securities purchase agreement with institutional and other accredited investors under which the investors have agreed to purchase a total of 9,684,000 shares of common stock and 11,368,500 shares of newly authorized Series B Preferred Stock in a private placement for aggregate gross proceeds of ~$100.0 million. The purchase price will be $4.75 for each share of common stock and $4.75 for each share of Series B Preferred Stock. The total volume of 10.48 Million shares held in the session was surprisingly higher than its average volume of 278.79 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -29.30%, and looking further price to next year’s EPS is -26.50%.
Shares of Qiagen NV (NASDAQ:QGEN) [Trend Analysis] runs in leading trade, it surging 0.50% to traded at $22.24. The firm has price volatility of 1.82% for a week and 1.66% for a month. Its beta stands at 0.90 times. Qiagen announced another extension of the offer period for the acquisition of Exiqon to May 19, 2016 (QGEN). “We have made a compelling and fair offer that is not only appreciated by Exiqon’s board of directors and its largest shareholders”, said Peer Schatz, CEO of QIAGEN N.V.
“During the first extension period, additional retail shareholders also have recognized that the offer values the company appropriately and have tendered their shares. We extend the offer one more time and trust that in the end we will reach the 90 % acceptance rate necessary to complete the transaction.” Narrow down four to firm performance, its weekly performance was 3.59% and monthly performance was 2.39%. The stock price of QGEN is moving up from its 20 days moving average with 3.02% and isolated negatively from 50 days moving average with -0.25%.